Login to Your Account



MORE DATA DUE THIS WEEK

Secondary BENEFIT in ALS trial? Cytokinetics’ Tirasemtiv might be saved post-blowup

By Randy Osborne
Staff Writer

Monday, April 28, 2014
The phase IIb failure of tirasemtiv in amyotrophic lateral sclerosis (ALS) jolted Wall Street, though some analysts had been wary from the start about the chances for the fast skeletal muscle troponin activator.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription